Sailing against the current, heading towards a new direction

On January 20, 2024, in the face of the current difficult environment for drug sales, we interviewed Mr. Wang Liangquan, the General Manager of Fujian Zhonghe Pharmaceutical Co., Ltd. Mr. Wang Liangquan will discuss the search for new profit growth points, the goals and plans for 2024, the implementation of brand marketing to achieve brand breakthroughs, and the trends of future big health brand marketing, fully preparing for the future development of the brand. Mr. Wang Liangquan's company, Fujian Zhonghe Pharmaceutical Co., Ltd., was established in 2010 and is a high-tech pharmaceutical enterprise specializing in drug research and development, production, and sales; The company has advanced equipment, strong technical strength, internationally advanced production and quality testing facilities, tablet, capsule, granule, oral liquid production lines, and traditional Chinese medicine pretreatment and extraction workshops, as well as a high-quality management, production, and marketing team; The enterprise takes "Zhonghe Medicine, Benefiting All" as its purpose, adheres to the business philosophy of "quality first, technology driven development", always insists on people-oriented management, and is committed to creating international pharmaceutical brand products to provide high-quality medicine for human health.

Zhonghe Pharmaceutical involves multiple production lines for tablets, capsules, granules, oral suspensions, mixtures, oral solutions, and pre-treatment and extraction of traditional Chinese medicine. In the current era of low growth in drug sales, Mr. Wang Liangquan stated that Zhonghe Pharmaceutical needs to upgrade its product categories and find new profit growth points.

Firstly, the company has national products: Almond Cough Relief Oral Liquid and Chunmei Granules, which have only two approvals nationwide, as well as ferrous sulfate tablets that are currently undergoing consistency evaluation. These are all essential products in the market. The company will adopt a strategy of attracting investment and implementing graded and classified management to deeply cultivate these three main products in the clinical and OTC markets, striving for maximum efficiency. Secondly, the company will also do a good job in coordinating marketing for other categories, achieving academic complementarity between products, implementing joint medication in marketing, segmenting markets in channels, strictly controlling prices for sales, making long-term plans strategically, flexibly applying tactics, understanding trade-offs, and strictly managing market order. In marketing, we do not seek rapid growth, but only strive for steady progress, standardized operations, and win the future.

Then we should actively embrace Internet marketing, adopt digital marketing, and achieve the return of product value and annual business plan goals through a variety of sales platforms, so as to gradually achieve category upgrading and find new profit growth points in the current era of low growth of drug sales.

Zhonghe Medicine should also follow the trend. In the face of the current change in user's catalytic habits, many pharmaceutical enterprises also follow the trend. Mr. Wang Liangquan said that in terms of brand development, Sinopharm should also take the initiative to embrace Internet advertising, improve users' awareness and recognition of Sinopharm from multiple perspectives, and try their best to achieve brand breakthrough in the era of stock competition. Mr. Wang Liangquan believes that there will be six major trends in the future marketing of big health brands: the rise of digital marketing is inevitable, clinical and academic marketing will become more in-depth, the sales volume of centralized procurement products will soar, the trend of bidding based procurement in chain pharmacies will prevail, multi-channel sales will become the mainstream growth point, and marketing innovation will become the main research topic and direction of the industry. Mr. Wang Liangquan stated that in the face of 2024, all plans and preparations have been made, and the goals are very clear. While achieving multi-channel and multi platform sales, the overall goal is to achieve a growth rate of over 50% on the basis of 2023. In the difficult situation of [SEP], Fujian Zhonghe Pharmaceutical Co., Ltd. is not afraid of difficulties and faces them head-on. Mr. Wang Liangquan's expectations for 2024 are even more like "sailing against the current and moving towards a new direction".